Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia Ranked As Second Most Expensive Country For Clinical Trials; Medicines Australia Calls For Reform

This article was originally published in PharmAsia News

Executive Summary

A strong currency and cumbersome rules have contributed to Australia becoming the second-most expensive country for clinical trials, and neighboring countries are taking advantage.

You may also be interested in...



Australia's New R&D Tax Credit Expected To Inject Funds Into Local Biotech Industry - And Multinational Subsidiaries?

MELBOURNE, Australia - Many in the Australian life sciences industry view the nation's new R&D Tax Credit, which became law in August 2011 with the passing of the Tax Laws Amendment (Research and Development) Bill 2010, as a marked improvement on the R&D Tax Concession it replaces

Australia Department Of Innovation Releases 10-Year Plan On Pharma Strategy

PERTH, Australia - Australia's Minister for Innovation, Industry, Science and Research, Senator Kim Carr, has released a sweeping report that outlines a 10-year plan for the country's pharmaceutical and biotech industry

Prima Shifts Focus To LAG-3 After Immutep Deal

The Australian immuno-therapeutics developer Prima BioMed has had a change of focus in recent months since buying Paris-based Immutep in late 2014. Prima’s lead product used to be its CVac cancer vaccine, but it has now shifted strategic priority to an LAG-3 immune checkpoint receptor that came with the acquisition.

Topics

Related Companies

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel